Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better

被引：0

作者：

Franchini, Massimo ^{[1
]}

机构：

[1] Azienda Osped Univ Parma, Serv Immunoematol & Trasfus, Parma, Italy

来源：

BLOOD TRANSFUSION | 2010年 / 8卷 / 04期

关键词：

PREVIOUSLY UNTREATED PATIENTS; IMMUNE TOLERANCE INDUCTION; INHIBITOR DEVELOPMENT; CHILDREN; PURITY; EPIDEMIOLOGY; PRODUCTS; EFFICACY; COMPLEX; RISK;

D O I：

10.2450/2010.0067.10

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：292 / 296

页数：5

共 48 条

[11]

Dimichele DM, 2010, HAEMOPHILIA, V16, P29

[12] Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development [J].

Ettingshausen, C. Escuriola ;

Kreuz, W. .

HAEMOPHILIA, 2006, 12 :102-106

[13] Forum on: the role of recombinant factor VIII in children with severe haemophilia A [J].

Franchini, M. ;

Coppola, A. ;

Molinari, A. C. ;

Santoro, C. ;

Schinco, P. ;

Speciale, V. ;

Tagliaferri, A. .

HAEMOPHILIA, 2009, 15 (02) :578-586

[14]

Franchini M, 2010, THROMB HAEMOST

[15] Recombinant Factor VIII Concentrates [J].

Franchini, Massimo ;

Lippi, Giuseppe .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2010, 36 (05) :493-497

[16] Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of Recombinant Factor VIII replacement therapy [J].

Giles, AR ;

Rivard, GE ;

Teitel, J ;

Walker, I .

TRANSFUSION SCIENCE, 1998, 19 (02) :139-148

[17] The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors [J].

Gomperts, E. D. .

HAEMOPHILIA, 2006, 12 (06) :573-578

[18] The incidence of inhibitor development according to specific mutations - and treatment? [J].

Goodeve, A .

BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 :S17-S21

[19] Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A [J].

Goudemand, J ;

Rothschild, C ;

Demiguel, V ;

Vinciguerrat, C ;

Lambert, T ;

Chambost, H ;

Borel-Derlon, A ;

Claeyssens, S ;

Laurian, Y ;

Calvez, T .

BLOOD, 2006, 107 (01) :46-51

[20] Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A:: the CANAL cohort study [J].

Gouw, Samantha C. ;

van der Bom, Johanna G. ;

Auerswald, Guenter ;

Ettinghausen, Carmen Escuriola ;

Tedgard, Ulf ;

van den Berg, H. Marijke .

BLOOD, 2007, 109 (11) :4693-4697

← 1 2 3 4 5 →